The 3D Systems lawsuit, filed in the United States District Court for the District of Delaware, represents everyone who purchased company securities during this crucial period. The company’s financial reports show disappointing results. Q4 non-GAAP earnings-per-share reached -$0.19 and missed consensus estimates by $0.08. Sales revenue hit $111 million—a 3.4% year-over-year decline that missed expectations by $4.17 million. The company’s full-year 2024 sales fell to $440.1 million, showing a 10% decrease from the previous year.

Investors who lost money on their 3D Systems investments during this period should note the August 12, 2025 deadline to ask for appointment as lead plaintiff. On top of that, the company’s financial health shows concerning trends with a trailing 12-month net loss of $276.58 million and revenue of $432 million as of March 31, 2025.

3D Systems Faces Securities Fraud Allegations

The 3D Systems class action lawsuit against 3D Systems Corporation centers on material misrepresentations between August 13, 2024 and May 12, 2025. The U.S. District Court for the District of Delaware received the complaint that details claims against the company and its executives, including CEO Jeffrey Graves and CFO Jeffrey Creech.

Company accused of misleading investors on financial resilience in 3D Systems Lawsuit

The 3D Systems class action lawsuit claims 3D Systems misled shareholders about its financial health during challenging market conditions. Legal documents show the company made false and misleading statements to “artificially inflate” market prices of its securities. Two main issues stand at the heart of this alleged deception.

Plaintiffs say 3D Systems “understated the impact of weakened customer spending” on its operations. The company painted an unrealistic picture of resilience instead of acknowledging industry-wide challenges in the 3D printing sector. Revenue declined by 10% in 2024 and 8% in Q1 2025, which supports these claims.

Analysts spotted red flags in the company’s financial reporting. The truth came to light when 3D Systems announced poor quarterly results in March and May 2025. The stock price dropped more than 20% each time. These inconsistencies in financial reporting have strengthened the case for investor litigation.

The 3D Systems class action lawsuit points out these misrepresentations became clear in aerospace and automotive sectors. Customer spending dropped and this affected the company’s performance. In spite of that, 3D Systems kept portraying its results as resilient.

Allegations tied to regenerative medicine revenue projections

The second key allegation focuses on 3D Systems’ partnership with United Therapeutics Corporation for developing 3D-printed lungs. This regenerative medicine program could have brought substantial revenue to the company.

3D Systems disclosed a $9.00 million revenue reduction for Q4 2024 from its Regenerative Medicine program in March 2025. The company attributed this adjustment to “a change in accounting estimates” related to “the now predicted use of pre-clinical human decedent testing”. These changes “led to refinement of the milestone technical criteria”.

The 3D Systems class action lawsuit states 3D Systems didn’t reveal how updated milestone criteria in this partnership would hurt program revenue. The company allegedly hid these issues to maintain appearances of financial stability.

Legal experts find the timing suspicious. The $9.00 million write-down happened with a 21% stock plunge, which raises questions about earnings manipulation. The plaintiffs’ attorneys highlight three key points:

• 3D Systems didn’t disclose risks around milestone dependency in the regenerative medicine program
• Previous quarters might have shown inflated revenue before the sudden Q4 write-down
• The company ignored or concealed warning signs about inventory and demand issues

Shareholders and other class members claim these “wrongful acts and omissions” caused them “significant losses and damages”.

Investors File $100M Class Action Lawsuit

Law firms have started legal proceedings against 3D Systems Corporation. They represent investors who bought securities during a specific period. The class action lawsuit seeks damages up to $100 million to recover losses from alleged securities fraud.

Class period in 3D Systems Lawsuit spans August 13, 2024 to May 12, 2025

The 3D Systems class action lawsuit covers investors who bought or acquired 3D Systems securities between August 13, 2024 and May 12, 2025. This timeframe, known as the “Class Period,” saw company announcements and financial disclosures that allegedly contained false or misleading statements. Legal notices confirm that only trades made during this period qualify for potential recovery.

The class action represents “all persons and entities other than Defendants that purchased or otherwise acquired 3D Systems securities” during this period. Both individual and institutional investors might qualify if they traded within these dates.

3D Systems Lawsuit filed in U.S. District Court for the District of Delaware

The United States District Court for the District of Delaware received the official case filing. Legal documents show the case number as 1:25-cv-00734 or 25-cv-00734 in some notices. Lawyers submitted the complaint on June 13, 2025.

“Herbermann v. 3D Systems Corp.” seeks damages for alleged violations of federal securities laws. The lawsuit pursues remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. These laws address securities fraud and corporate officer liability.

Lead plaintiff deadline set for August 12, 2025

Investors thinking about joining this class action should note a significant deadline. The court set August 12, 2025, as the final date for potential lead plaintiffs to submit their motions. This deadline applies to all participating law firms.

Lead plaintiff candidates must ask for court appointment before this deadline. The court usually picks the investor with the largest financial stake who shows typical claims compared to other class members.

Affected investors don’t need to pay upfront costs. Securities class action firms take payment only after successful recovery of damages. This arrangement lets investors seek recovery without financial risks.

The court hasn’t certified any class yet. Until then, investors need their own lawyer to represent them. They can choose their counsel, join existing representation, or stay an absent class member. An investor’s share in any future recovery doesn’t depend on being lead plaintiff.

If you suffered substantial losses and wish to serve as lead plaintiff of the 3D Systems class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].

The 3D Systems class action lawsuit claims 3D Systems made false and misleading statements about its business operations during the Class Period. These statements allegedly inflated stock prices artificially and caused investor losses at the time the truth came out.

Financial Disclosures Trigger Market Fallout

The 3D Systems class action lawsuit stems from two back-to-back earnings reports that shook investor confidence in the company’s financial health.

Q4 and Q1 earnings miss expectations

3D Systems started having money troubles when they released their fourth quarter 2024 results in March 2025. The company’s Q4 revenue came in at $111 million, which was 3% less than what they made in 2023. This number fell below what analysts expected – $115.17 million.

The news got worse when they reported a non-GAAP loss of $0.19 per share in Q4. This was a big deal as it means that they missed analyst estimates by $0.08. Their Healthcare Solutions segment, which used to be reliable, saw revenue drop by 21% to $40.40 million compared to last year.

Things looked even bleaker after Q1 2025. Revenue dropped 8% from the previous year to $94.50 million, missing analyst targets of $99.50 million. The company’s Q1 non-GAAP loss grew to $0.21 per share, while analysts predicted a loss of $0.13. This 61.54% difference shocked investors.

Stock price drops over 45% across two earnings reports

These disappointing numbers sent 3D Systems’ stock into a nosedive. The stock immediately fell 21% to $2.15 after they released Q4 results on March 26, 2025.

The Q1 announcement on May 12, 2025 hit even harder. The stock crashed another 25.3% in just one day and settled at $1.87—showing a total drop of 42% from August 2024 peaks. Some sources reported the stock fell almost 30% in after-hours trading following the Q1 news.

Making matters worse, 3D Systems pulled back their full-year 2025 guidance. They blamed “the risk of protracted weakness in customer capital investment spending”. This unexpected move made investors even more nervous.

Revenue affected by milestone accounting changes

There’s another reason behind these financial misses – accounting changes related to the company’s regenerative medicine program with United Therapeutics.

During Q4 2024, 3D Systems changed how they handled “accounting estimates for Regenerative Medicine program milestone recognition“. This change reduced their revenue by $9 million that quarter.

The company said they needed to change because they added “pre-clinical human decedent testing” protocols, which meant updating their “milestone recognition criteria”. These accounting changes hurt their gross profit margins, which fell from 38.3% to 31.0% compared to last year.

3D Systems now faces yearly losses over $275 million and burns through about $69 million in cash each year. The missed financial targets, accounting changes, and withdrawn guidance created a perfect storm that led shareholders to file the 3D Systems class action lawsuit.

United Therapeutics Partnership Comes Under Scrutiny

3D Systems’ financial troubles stem from its high-profile partnership with United Therapeutics. Their collaboration, which represents advanced innovation in bioprinting human organs, focused on creating 3D-printed lung support structures. The partnership later expanded to include kidneys and livers, and now faces intense scrutiny amid securities fraud allegations.

Updated milestone criteria affect revenue recognition

The partnership’s controversy revolves around a major accounting adjustment from Q4 2024. 3D Systems made “a change in accounting estimate related to refinement of milestone recognition criteria” in its Regenerative Medicine program. This change led to a substantial $8.70 million revenue reduction that quarter.

The company linked this change to “the now predicted use of pre-clinical human decedent testing, successfully showed by our partner, United Therapeutics”. This technical explanation raised serious questions about timing and disclosure practices. The 3D Systems lawsuit claims 3D Systems hid the fact that updated milestone criteria would hurt program revenue.

Regenerative medicine program faces delays and uncertainty

The collaboration between 3D Systems and United Therapeutics wanted to create individual-specific manufactured lungs ready for human trials by 2023. Company executives had earlier mentioned they hoped “to have these personalized, manufactured lungs cleared for human trials in under five years”. They set an ambitious target of “creating an unlimited supply of tolerable transplanted organs”.

The program now faces extended timelines. These accounting adjustments “deferred revenue rather than recognizing it upfront”. This move changed the financial path of what 3D Systems had presented as the company’s growth driver.

Analysts question long-term viability of partnership

Financial experts worry about the partnership’s future. One analysis highlighted that “the Regenerative Medicine program, once a growth engine, now faces regulatory and technical hurdles. Its revenue decline suggests execution failures”.

The gap between operational progress and financial reporting has weakened investor confidence. Critics emphasize that without “clarity on the Regenerative Medicine program’s viability—or proof that governance reforms will prevent future misstatements—the stock remains a gamble”.

This partnership remains central to the class action lawsuit. The suit alleges 3D Systems “failed to disclose that updated ‘milestone criteria‘ under a partnership with biotech giant United Therapeutics Corp. to 3D print lungs would negatively affect 3D Systems’ revenue”.

Law Firms Compete to Represent Shareholders

Law firms are racing to represent shareholders in the 3D Systems class action lawsuit. Legal notices have flooded in since the case began in June 2025.

If you suffered substantial losses and wish to serve as lead plaintiff of the 3D Systems class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].

No cost to join the class action for eligible investors

Affected shareholders can participate with “no cost or obligation”. The competing firms, including the Law Offices of Timothy L. Miles work on contingency fees. This means investors can seek compensation “without payment of any out-of-pocket fees or costs”.

Legal notices make clear that “your ability to share in any recovery doesn’t require that you serve as a lead plaintiff”. Eligible investors who bought 3D Systems securities during the class period can recover damages. Their level of involvement in the litigation process doesn’t affect this right.

Conclusion

What This Means for Investors

This class action lawsuit against 3D Systems marks a pivotal moment for shareholders who bought company securities between August 13, 2024, and May 12, 2025. The deadline to apply for lead plaintiff status is August 12, 2025, and affected investors need to know their legal options.

The case reveals troubling claims about 3D Systems’ financial reporting. Two back-to-back earnings reports caused the stock price to

plummet by more than 45%, which devastated many investor portfolios. The company’s partnership with United Therapeutics raised red flags about how management recognized milestone-based revenue.

Shareholders now face crucial choices. The company adjusted its regenerative medicine program revenue by $9 million and missed financial targets quarter after quarter, which led to this legal action. Many law firms are competing to represent affected investors, and they work on contingency fees with no upfront costs.

This lawsuit highlights the 3D printing industry’s struggles. The company’s financial reports show revenue dropped 10% in 2024 and 8% in Q1 2025, while yearly losses hit $275 million. Their much-hyped plans to bioprint human organs now face questions about feasibility and timing.

The next few months will show if shareholders can recover their claimed losses. Eligible investors should decide about joining the case before August. Other manufacturing technology companies might learn valuable lessons about being transparent with shareholders during tough times as this legal battle unfolds.

Frequently Asked Questions about the 3D Systems lawsuit

Q1. What is the main allegation in the 3D Systems lawsuit? The lawsuit alleges that 3D Systems made false and misleading statements about its financial health and business prospects, particularly regarding its partnership with United Therapeutics for 3D-printed organs.

Q2. Who is eligible to participate in the 3D Systems lawsuit? Investors who purchased 3D Systems securities between August 13, 2024, and May 12, 2025, are eligible to join the class action lawsuit.

Q3. What caused the significant drop in 3D Systems’ stock price? The stock price fell over 45% following two consecutive disappointing earnings reports in March and May 2025, which revealed missed financial targets and accounting adjustments.

Q4. How has the United Therapeutics partnership affected 3D Systems? The partnership, once seen as a growth engine, now faces scrutiny due to delays, uncertainty, and a $9 million revenue reduction related to changes in milestone recognition criteria.

Q5. What should affected investors do if they want to join the lawsuit? If you suffered substantial losses and wish to serve as lead plaintiff of the 3D Systems class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].

Q6. What are the potential benefits of a 3D Systems lawsuit?

Class action lawsuits allow individual investors to collectively seek justice and compensation, which might be challenging to pursue individually. They also promote corporate accountability.

Q7 .How long will the 3D Systems lawsuit take to resolve?

The duration of class action lawsuits can vary significantly, depending on the complexity of the case, legal strategies, and whether settlements are reached. It could take several months to years.